Search

Displaying results 4391 - 4400 of 5261 in total
  1. Drug

    Phenoxybenzamine

    go.drugbank.com/drugs/DB00925
    ApprovedInvestigational

    An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.

  2. Drug

    Ofloxacin

    go.drugbank.com/drugs/DB01165
    ApprovedInvestigational

    A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

  3. Drug

    Mivacurium

    go.drugbank.com/drugs/DB01226
    ApprovedWithdrawn

    Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscul...

  4. Drug

    Pargyline

    go.drugbank.com/drugs/DB01626
    Approved

    Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.

  5. Drug

    5alpha-androstane-3beta,17alpha-diol

    go.drugbank.com/drugs/DB03926
    Experimental

    5alpha-androstane-3beta,17alpha-diol is the unspecified form of the steroid, normally a major metabolite of [testosterone] with androgenic activity.

  6. Drug

    Ponesimod

    go.drugbank.com/drugs/DB12016
    ApprovedInvestigational

    Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-ph...

  7. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    It is being developed by Avicena Group, Inc.

  8. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

  9. Drug

    Rocakinogene sifuplasmid

    go.drugbank.com/drugs/DB16316
    Investigational

    Rocakinogene sifuplasmid is under investigation in clinical trial NCT03491683 (INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-diagnosed Glioblastoma

  10. Drug

    ASP-8731

    go.drugbank.com/drugs/DB17696
    Investigational

    Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.[L46093]